S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
The gold catalyst we’ve waited for (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
The gold catalyst we’ve waited for (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
The gold catalyst we’ve waited for (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
The gold catalyst we’ve waited for (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Buffett's company owns nearly 24% of Occidental Petroleum
LON:AZN

AstraZeneca - AZN Share Forecast, Price & News

£111.67
+32.90 (+0.30%)
(As of 03/29/2023 08:25 AM ET)
Add
Compare
Today's Range
£111.16
£112.02
50-Day Range
£102.50
£115.78
52-Week Range
9,399
£128.28
Volume
189,943 shs
Average Volume
2.03 million shs
Market Capitalization
£173.09 billion
P/E Ratio
6,417.76
Dividend Yield
2.14%
Price Target
£118.72

AstraZeneca MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
6.1% Upside
£118.72 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars


AZN stock logo

About AstraZeneca (LON:AZN) Stock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

JP Morgan analyst: Oil to hit $380 per barrel
JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.
AstraZeneca's (LON:AZN) Dividend Will Be $1.45
JP Morgan analyst: Oil to hit $380 per barrel
JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.
AstraZeneca Bets On UK Listed Firm For Lung Diseases
AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript
AstraZeneca Q3 Preview: Can Shares Stay Strong?
Will AstraZeneca PLC (AZN) Deliver Promising Return?
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Company Calendar

Ex-Dividend for 3/27 Dividend
2/23/2023
Dividend Payable
3/27/2023
Today
3/29/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
83,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
£118.72
High Stock Price Forecast
£135
Low Stock Price Forecast
GBX 6,950
Forecasted Upside/Downside
+6.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
£3.29 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£44.35 billion
Cash Flow
GBX 286.96 per share
Book Value
GBX 2,390 per share

Miscellaneous

Outstanding Shares
1,550,000,000
Free Float
N/A
Market Cap
£172.98 billion
Optionable
Optionable
Beta
0.17

Key Executives

  • Mr. Pascal Soriot D.V.M. (Age 63)
    M.B.A., CEO & Exec. Director
    Comp: $4.75M
  • Dr. Aradhana Sarin M.D. (Age 47)
    CFO & Exec. Director
    Comp: $3.51M
  • Mr. Marc Dunoyer (Age 70)
    CEO of Alexion & Chief Strategy Officer
    Comp: $1.66M
  • Ms. Pam P. Cheng (Age 51)
    EVP of Operations & Information Technology and Member of External Sustainability Advisory Board
  • Mr. Chris Sheldon
    Head of Investor Relations
  • Mr. Jeffrey Pott
    Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board
  • Ms. Katarina Ageborg
    EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board
  • Gonzalo Vina
    Head of Global Media Relations
  • Dr. Menelas Pangalos Ph.D. (Age 55)
    EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
  • Dr. Ruud Dobber Ph.D.
    Exec. Vice-Pres of BioPharmaceuticals Bus. Unit













AZN Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AZN shares.
View AZN analyst ratings
or view top-rated stocks.

What is AstraZeneca's stock price forecast for 2023?

8 Wall Street research analysts have issued twelve-month target prices for AstraZeneca's stock. Their AZN share price forecasts range from GBX 6,950 to £135. On average, they predict the company's share price to reach £118.72 in the next twelve months. This suggests a possible upside of 6.6% from the stock's current price.
View analysts price targets for AZN
or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2023?

AstraZeneca's stock was trading at £112.18 at the beginning of the year. Since then, AZN stock has decreased by 0.7% and is now trading at £111.34.
View the best growth stocks for 2023 here
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a dividend on Thursday, February 9th. Shareholders of record on Thursday, February 23rd will be given a dividend of GBX 162.80 per share on Monday, March 27th. This represents a yield of 1.51%. The ex-dividend date is Thursday, February 23rd. This is a boost from the stock's previous dividend of GBX 76.40. The official announcement can be viewed at this link.
Read our dividend analysis for AZN
.

Is AstraZeneca a good dividend stock?

AstraZeneca (LON:AZN) pays an annual dividend of GBX 239 per share and currently has a dividend yield of 2.22%. The dividend payout ratio is 13,735.63%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZN.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Public (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately £111.34.

How much money does AstraZeneca make?

AstraZeneca (LON:AZN) has a market capitalization of £172.58 billion and generates £44.35 billion in revenue each year. The biopharmaceutical company earns £3.29 billion in net income (profit) each year or GBX 1.74 on an earnings per share basis.

How many employees does AstraZeneca have?

The company employs 83,100 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The official website for the company is www.astrazeneca.com. The biopharmaceutical company can be reached via phone at +44-20-73045000.

This page (LON:AZN) was last updated on 3/29/2023 by MarketBeat.com Staff